Search results for "Maxim"

showing 10 items of 1236 documents

Time flies when you maximize - Maximizers and satisficers perceive time differently when making decisions

2013

Three experiments assessed whether maximizing and satisficing decision-making types were associated with differences in perception of time, as a consequence of their different cognitive workloads. Findings showed that maximizers and satisficers perceived time differently during decision-making, but not during other tasks. In particular, compared to satisficers, maximizers tended to underestimate time while choosing, independently of the number of options and the specific task requirements. Satisficers instead tended to underestimate time only when the number of options or the task requirements were more challenging. Our findings suggest that the perception of time may serve as a measure of …

MaleChoice overloadProcess (engineering)Decision MakingTime perceptionExperimental and Cognitive PsychologyCognitionGeneral MedicineTime perceptionMaximizingTask (project management)Young AdultCognitionArts and Humanities (miscellaneous)Developmental and Educational PsychologySatisficingHumansSatisficingFemaleCognitive workloadPsychologyMaximizing Satisficing Time perception Choice overloadSocial psychologyCognitive psychology
researchProduct

Axial neck rotation strength in neutral and prerotated postures.

2003

Abstract Objective. To characterize isometric rotation strength in the neutral and in different prerotated positions of the neck. Design. This was a descriptive study involving maximal isometric strength measurements of the cervical musculature. Background. The literature contains only a few studies pertaining to strength levels of the neck rotator muscles in the neutral position. None of these studies have dealt in detail with maximal neck strength in selected prerotation positions. Method. Twenty healthy men volunteered as subjects. Maximal axial rotation strength of the neck muscles was measured in a neutral position and bilaterally at 30° and 60° rotation using the isometric neck streng…

MaleNeck painRotationMovementPostureBiophysicsNeck rotationIsometric exerciseAnatomyRotationNeck musclesmedicine.anatomical_structureNeck MusclesMaximal strengthmedicineHumansOrthopedics and Sports MedicineRotator cuffmedicine.symptomRange of Motion ArticularRange of motionMathematicsClinical biomechanics (Bristol, Avon)
researchProduct

Phase ia/ii, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematolo…

2013

Panobinostat is a potent oral pandeacetylase inhibitor that leads to acetylation of intracellular proteins, inhibits cellular proliferation and induces apoptosis in leukemic cell lines. A phase Ia/II study was designed to determine the maximum-tolerated dose (MTD) of daily panobinostat, administered on two schedules: three times a week every week or every other week on a 28-day treatment cycle in patients with advanced hematologic malignancies. The criteria for hematologic dose-limiting toxicities differed between patients with indications associated with severe cytopenias at baseline (leukemia and myeloid disorders) and those less commonly associated with baseline cytopenias (lymphoma and …

MaleOncologyCancer ResearchIndolesMyeloidhodgkin lymphomahydroxamic acidAdministration Oralresponse criteriaPharmacologyHydroxamic Acidst-cell lymphomaHistoneschemistry.chemical_compoundhemic and lymphatic diseasesAged 80 and overHematologyMiddle AgedLeukemiaTreatment Outcomemedicine.anatomical_structuremyelomaOncologyvorinostatHematologic NeoplasmsFemaleAdultmedicine.medical_specialtypanobinostatrefractory multiple-myelomaMaximum Tolerated DoseAntineoplastic AgentsmyelofibrosisNeutropeniahistone deacetylase inhibitorsmyelodysplastic disordersDrug Administration ScheduleYoung AdultInternal medicinePanobinostatmedicineHumansIn patientAdverse effectMyelofibrosisAgedNeoplasm Staginginternational-working-groupacetylationbusiness.industrymedicine.diseaseLymphomachemistryhistone deacetylasehypoxia-inducible factor-1-alphalbh589business
researchProduct

Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in pat…

2013

Abstract Background This phase I/II-trial assessed the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of neoadjuvant radiochemotherapy (RCT) with docetaxel and oxaliplatin in patients with locally advanced adenocarcinoma of the oesophagogastric junction. Methods Patients received neoadjuvant radiotherapy (50.4 Gy) together with weekly docetaxel (20 mg/m2 at dose level (DL) 1 and 2, 25 mg/m2 at DL 3) and oxaliplatin (40 mg/m2 at DL 1, 50 mg/m2 at DL 2 and 3) over 5 weeks. The primary endpoint was the DLT and the MTD of the RCT regimen. Secondary endpoints included overall response rate (ORR) and progression-free survival (PFS). Results A total of 24 patients were included. F…

MaleOncologyCancer ResearchTime FactorsEsophageal NeoplasmsOrganoplatinum Compoundsmedicine.medical_treatmentMedizinKaplan-Meier EstimateDocetaxellaw.inventionRandomized controlled triallawGermanyProspective StudiesIsraelProspective cohort studyNeoadjuvant therapyChemoradiotherapyMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensNeoadjuvant TherapyOxaliplatinOesophagogastric cancer oxaliplatinTreatment OutcomeDocetaxelOncologyNeoadjuvant radiochemotherapyAdenocarcinomaFemaleTaxoidsEsophagogastric JunctiontherapeuticsResearch Articlemedicine.drugAdultmedicine.medical_specialtyMaximum Tolerated DoseAntineoplastic AgentsAdenocarcinomalcsh:RC254-282Disease-Free SurvivalStomach NeoplasmsInternal medicinemedicineGeneticsHumansddc:610neoplasmsAgedDose-Response Relationship Drugbusiness.industryChemoradiotherapy Adjuvantmedicine.diseasedigestive system diseasesOxaliplatinClinical trialbusinessChemoradiotherapy
researchProduct

An explorative study to assess the association between health-related quality of life and the recommended phase II dose in a phase I trial: idarubici…

2016

Objectives The objective of this study was to explore the association between health-related quality of life (HRQoL) and the recommended phase 2 dose in a phase I clinical trial according to the Time to HRQoL deterioration approach (TTD). Setting This is a phase I dose-escalation trial of transarterial chemoembolisation (TACE) with idarubicin-loaded beads performed in cirrhotic patients with hepatocellular carcinoma. Patients had to complete the EORTC QLQ-C30 HRQoL questionnaire at baseline and at days 15, 30 and 60 after TACE. Participants Patients aged ≥18 years with HCC unsuitable for curative treatments were evaluated for the study (N=21). Primary and secondary outcome measurements The …

MaleOncologyHealth-related Quality of LifePhases of clinical research[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineQuality of life1506FatigueAntibiotics AntineoplasticLiver NeoplasmsGeneral MedicineMiddle Aged3. Good healthOncology030220 oncology & carcinogenesisHepatocellular carcinomaToxicityFemale[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology030211 gastroenterology & hepatology1717medicine.drugmedicine.medical_specialtyCarcinoma HepatocellularMaximum Tolerated Dose1722Pain[SDV.CAN]Life Sciences [q-bio]/CancerPhase 1Disease-Free Survival03 medical and health sciencesInternal medicineCarcinomamedicineHumansIdarubicinChemoembolization TherapeuticAgedHealth-related Quality of ifeOncology clinical trialHealth related quality of lifebusiness.industryResearchlongitudinal analysis[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterologyphase Imedicine.diseaseSurgeryTime to deteriorationMaximum tolerated doseQuality of LifeIdarubicinbusinessBMJ Open
researchProduct

Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-…

2009

Abstract Background This phase I dose-escalation study was designed to determine the maximum tolerated dose (MTD) and recommended dose of cetuximab administered on an every-second-week schedule to patients with metastatic colorectal cancer, on the basis of safety, pharmacokinetic and pharmacodynamic evaluation. Patients and methods The study comprised two parts: a 6-week cetuximab monotherapy dose-escalation phase and a subsequent combination therapy phase, during which patients received cetuximab, at the same dose/schedule as in the monotherapy phase, followed by irinotecan plus infusional 5-fluorouracil/folinic acid (FOLFIRI). Patients in the control group received cetuximab as a 400 mg/m…

MaleOncologymedicine.medical_specialtyMaximum Tolerated DoseCombination therapyColorectal cancerLeucovorinCetuximabAntibodies Monoclonal HumanizedIrinotecanImmunoenzyme TechniquesFolinic acidPharmacokineticsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansTissue DistributionneoplasmsAgedDose-Response Relationship DrugCetuximabbusiness.industryAntibodies MonoclonalHematologyMiddle Agedmedicine.diseasedigestive system diseasesSurgeryErbB ReceptorsSurvival RateIrinotecanTreatment OutcomeOncologyPharmacodynamicsFOLFIRICamptothecinFemaleFluorouracilColorectal Neoplasmsbusinessmedicine.drugAnnals of Oncology
researchProduct

Age- and sex-dependent differences in patients with severe asthma included in the German Asthma Net cohort.

2020

Severe asthma affects less than 5% of asthmatics, but is associated with high costs and increased mortality. The aim of this study was to assess age- and sex-dependent differences in this patient group.Retrospective analysis of 1317 children and adults with severe asthma who are included in the German Asthma Net registry.There were more adults than children in the registry and patients' mean age was 52. Apart from children18 years, there were more women (57%) than men. The age of first diagnosis ranged from 0 to 76 years. 38% of patients had a positive bronchial reversibility after short acting bronchodilators. Quality of life, FEV1 and MEF 25 decreased with older age whereas treatment with…

MalePediatricsDiseaseOmalizumabSeverity of Illness IndexGermanCohort Studies0302 clinical medicineGermany030212 general & internal medicineAnti-Asthmatic AgentsChildAged 80 and overAge FactorsAntibodies MonoclonalMiddle AgedBronchodilator AgentsChild PreschoolCohortlanguageFemalePulmonary and Respiratory MedicineAdultmedicine.medical_specialtyAdolescentSevere asthmamacromolecular substancesAge and sex03 medical and health sciencesYoung AdultSex FactorsAge groupsmedicineHumansIn patientGlucocorticoidsAsthmaAgedMaximal Expiratory Flow RateRetrospective Studiesbusiness.industryInfantImmunoglobulin Emedicine.diseaselanguage.human_languageAsthmarespiratory tract diseases030228 respiratory systemQuality of LifebusinessRespiratory medicine
researchProduct

Meta-analysis of the increase in height in maxillary sinus elevations with osteotome

2011

Objectives: To compare the different variations of sinus elevation techniques with osteotomes, to evaluate the increase in height achieved, and to quantify the osseointegration periods and the success rates for the implants placed. Study Design: A meta-analytic study with descriptive statistics was carried out on sinus elevations using osteotomes, analyzing a total of 11 articles published between the years 2003 and 2008. Results: Summers’ classic technique for performing sinus elevations with osteotomes differs from the current techniques being used with respect to the use of drills, the manner in which the sinus floor is fractured and how the sinus membrane is lifted, and especially on th…

MaleSinus Floor AugmentationTime FactorsMaxillary sinusmedicine.medical_treatmentDentistrySinus Floor AugmentationOsteotomyOsseointegrationOsseointegrationMaximum gainmedicineHumansGeneral DentistrySinus (anatomy)business.industryReview-Article:CIENCIAS MÉDICAS [UNESCO]Osteotomymedicine.anatomical_structureOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSinus elevationOsteotomeSurgeryFemaleOral SurgerybusinessMedicina Oral, Patología Oral y Cirugía Bucal
researchProduct

Antiepileptic effect of dimethyl sulfoxide in a rat model of temporal lobe epilepsy.

2012

Dimethyl sulfoxide (DMSO) is an amphipathic molecule widely used to solubilize water-insoluble compounds. In many studies it was reported that DMSO is capable of affecting several biological processes, thus resulting in a potential cause for the misinterpretation of experimental data. Recent papers showed that DMSO modified the brain bioelectric activity in animal models of epilepsy. In an in vivo model of temporal lobe epilepsy in the rat, we examined the effects of different doses (10%, 50% and 100%) of DMSO on the maximal dentate activation (MDA). The results show that DMSO induced a dose-dependent significant reduction of the electrically induced paroxysmal activity.

MaleTreatment outcomeRat modelAction PotentialsPharmacologySettore BIO/09 - FisiologiaTemporal lobeEpilepsychemistry.chemical_compoundIn vivomedicineAnimalsHumansDimethyl SulfoxideRats WistarTemporal lobe epilepsyDose-Response Relationship DrugChemistryDimethyl sulfoxideGeneral Neurosciencemedicine.diseaseRatsDose–response relationshipDisease Models AnimalMaximal dentate activationTreatment OutcomeBiochemistryCerebellar NucleiEpilepsy Temporal LobeSolubilizationAnticonvulsantsNeuroscience letters
researchProduct

Dietary Quality Changes According to the Preceding Maximum Weight: A Longitudinal Analysis in the PREDIMED-Plus Randomized Trial

2020

One-year dietary quality change according to the preceding maximum weight in a lifestyle intervention program (PREDIMED-Plus trial, 55–75-year-old overweight or obese adults; n = 5695) was assessed. A validated food frequency questionnaire was used to assess dietary intake. A total of 3 groups were made according to the difference between baseline measured weight and lifetime maximum reported weight: (a) participants entering the study at their maximum weight, (b) moderate weight loss maintainers (WLM), and (c) large WLM. Data were analyzed by General Linear Model. All participants improved average lifestyle. Participants entering the study at their maximum weight were the most susceptible …

Malecumplimiento del pacienteMediterranean diethumanosOverweightDiet Mediterraneanlaw.inventionencuestas sobre dietasClinical trials0302 clinical medicineRandomized controlled trialBehavior TherapyWeight losslawestudios prospectivosWeight managementMedicineLongitudinal StudiesProspective Studies030212 general & internal medicineskin and connective tissue diseasesmediana edadancianoNutrition and Dieteticssobrepesodietaresultado del tratamientoMaximum weightmodelos linealesMiddle AgedWeight Reduction ProgramsTreatment OutcomeBody imageDiet qualityCardiovascular Diseasesestilo de vidaprogramas de reducción de pesoFemaleDietaterapia conductistadietary patternDiet Healthypérdida de pesomedicine.symptommaximum weightlcsh:Nutrition. Foods and food supplybody imageenfermedades cardiovascularesPes corporalDietary patternlcsh:TX341-641030209 endocrinology & metabolismDiet SurveysArticle03 medical and health sciencesMediterranean dietWeight LossHumansObesityLife StyleobesidadAgedGeneral linear modelbusiness.industryPREDIMED-PlusBody weightOverweightPredimedDietLinear ModelsPatient Complianceestudios longitudinalesBody-Weight Trajectorysense organsbusinessAssaigs clínicsFood ScienceDemography
researchProduct